166 related articles for article (PubMed ID: 37279301)
1. Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial.
Fehlings MG; Moghaddamjou A; Harrop JS; Stanford R; Ball J; Aarabi B; Freeman BJC; Arnold PM; Guest JD; Kurpad SN; Schuster JM; Nassr A; Schmitt KM; Wilson JR; Brodke DS; Ahmad FU; Yee A; Ray WZ; Brooks NP; Wilson J; Chow DS; Toups EG; Kopjar B
J Neurotrauma; 2023 Sep; 40(17-18):1878-1888. PubMed ID: 37279301
[TBL] [Abstract][Full Text] [Related]
2. Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial.
Chow DS; Nguyen A; Park J; Wu L; Toups EG; Harrop JS; Guest JD; Schmitt KM; Aarabi B; Fehlings MG; Boakye M; Grossman RG
J Neurotrauma; 2023 Sep; 40(17-18):1889-1906. PubMed ID: 37130044
[TBL] [Abstract][Full Text] [Related]
3. Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial.
Fehlings MG; Nakashima H; Nagoshi N; Chow DS; Grossman RG; Kopjar B
Spinal Cord; 2016 Jan; 54(1):8-15. PubMed ID: 26099215
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial.
Derakhshanrad N; Saberi H; Yekaninejad MS; Joghataei MT; Sheikhrezaei A
J Neurosurg Spine; 2018 Jul; 29(1):97-107. PubMed ID: 29701561
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
6. A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury.
Grossman RG; Fehlings MG; Frankowski RF; Burau KD; Chow DS; Tator C; Teng A; Toups EG; Harrop JS; Aarabi B; Shaffrey CI; Johnson MM; Harkema SJ; Boakye M; Guest JD; Wilson JR
J Neurotrauma; 2014 Feb; 31(3):239-55. PubMed ID: 23859435
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
Fehlings MG; Badhiwala JH; Ahn H; Farhadi HF; Shaffrey CI; Nassr A; Mummaneni P; Arnold PM; Jacobs WB; Riew KD; Kelly M; Brodke DS; Vaccaro AR; Hilibrand AS; Wilson J; Harrop JS; Yoon ST; Kim KD; Fourney DR; Santaguida C; Massicotte EM; Kopjar B
Lancet Neurol; 2021 Feb; 20(2):98-106. PubMed ID: 33357512
[TBL] [Abstract][Full Text] [Related]
8. An Introduction to the North American Clinical Trials Network for Spinal Cord Injury Special Edition: Reflections on Accomplishments and a Look to the Future.
Fehlings MG; Neal CJ; Hejrati N; Harrop JS; Toups EG; Guest JD
J Neurotrauma; 2023 Sep; 40(17-18):1811-1816. PubMed ID: 37668560
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of riluzole in the treatment of spinal cord injury: a systematic review of the literature.
Srinivas S; Wali AR; Pham MH
Neurosurg Focus; 2019 Mar; 46(3):E6. PubMed ID: 30835675
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of granulocyte colony-stimulating factor for spinal cord injury.
Koda M; Hanaoka H; Fujii Y; Hanawa M; Kawasaki Y; Ozawa Y; Fujiwara T; Furuya T; Ijima Y; Saito J; Kitamura M; Miyamoto T; Ohtori S; Matsumoto Y; Abe T; Takahashi H; Watanabe K; Hirano T; Ohashi M; Shoji H; Mizouchi T; Kawahara N; Kawaguchi M; Orita Y; Sasamoto T; Yoshioka M; Fujii M; Yonezawa K; Soma D; Taneichi H; Takeuchi D; Inami S; Moridaira H; Ueda H; Asano F; Shibao Y; Aita I; Takeuchi Y; Mimura M; Shimbo J; Someya Y; Ikenoue S; Sameda H; Takase K; Ikeda Y; Nakajima F; Hashimoto M; Hasue F; Fujiyoshi T; Kamiya K; Watanabe M; Katoh H; Matsuyama Y; Hasegawa T; Yoshida G; Arima H; Yamato Y; Oe S; Togawa D; Kobayashi S; Akeda K; Kawamoto E; Imai H; Sakakibara T; Sudo A; Ito Y; Kikuchi T; Takigawa T; Morita T; Tanaka N; Nakanishi K; Kamei N; Kotaka S; Baba H; Okudaira T; Konishi H; Yamaguchi T; Ito K; Katayama Y; Matsumoto T; Matsumoto T; Kanno H; Aizawa T; Hashimoto K; Eto T; Sugaya T; Matsuda M; Fushimi K; Nozawa S; Iwai C; Taguchi T; Kanchiku T; Suzuki H; Nishida N; Funaba M; Sakai T; Imajo Y; Yamazaki M
Brain; 2021 Apr; 144(3):789-799. PubMed ID: 33764445
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Controlled Trial of Local Delivery of a Rho Inhibitor (VX-210) in Patients with Acute Traumatic Cervical Spinal Cord Injury.
Fehlings MG; Chen Y; Aarabi B; Ahmad F; Anderson KD; Dumont T; Fourney DR; Harrop JS; Kim KD; Kwon BK; Lingam HK; Rizzo M; Shih LC; Tsai EC; Vaccaro A; McKerracher L
J Neurotrauma; 2021 Aug; 38(15):2065-2072. PubMed ID: 33559524
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
15. Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside.
Nagoshi N; Nakashima H; Fehlings MG
Molecules; 2015 Apr; 20(5):7775-89. PubMed ID: 25939067
[TBL] [Abstract][Full Text] [Related]
16. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
17. Riluzole for Degenerative Cervical Myelopathy: A Secondary Analysis of the CSM-PROTECT Trial.
Fehlings MG; Pedro KM; Alvi MA; Badhiwala JH; Ahn H; Farhadi HF; Shaffrey CI; Nassr A; Mummaneni P; Arnold PM; Jacobs WB; Riew KD; Kelly M; Brodke DS; Vaccaro AR; Hilibrand AS; Wilson J; Harrop JS; Yoon ST; Kim KD; Fourney DR; Santaguida C; Massicotte EM; Huang P
JAMA Netw Open; 2024 Jun; 7(6):e2415643. PubMed ID: 38904964
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
19. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.
Casha S; Zygun D; McGowan MD; Bains I; Yong VW; Hurlbert RJ
Brain; 2012 Apr; 135(Pt 4):1224-36. PubMed ID: 22505632
[TBL] [Abstract][Full Text] [Related]
20. Study protocol for the G-SPIRIT trial: a randomised, placebo-controlled, double-blinded phase III trial of granulocyte colony-stimulating factor-mediated neuroprotection for acute spinal cord injury.
Koda M; Hanaoka H; Sato T; Fujii Y; Hanawa M; Takahashi S; Furuya T; Ijima Y; Saito J; Kitamura M; Ohtori S; Matsumoto Y; Abe T; Watanabe K; Hirano T; Ohashi M; Shoji H; Mizouchi T; Takahashi I; Kawahara N; Kawaguchi M; Orita Y; Sasamoto T; Yoshioka M; Fujii M; Yonezawa K; Soma D; Taneichi H; Takeuchi D; Inami S; Moridaira H; Ueda H; Asano F; Shibao Y; Aita I; Takeuchi Y; Mimura M; Shimbo J; Someya Y; Ikenoue S; Sameda H; Takase K; Ikeda Y; Nakajima F; Hashimoto M; Ozawa T; Hasue F; Fujiyoshi T; Kamiya K; Watanabe M; Katoh H; Matsuyama Y; Yamamoto Y; Togawa D; Hasegawa T; Kobayashi S; Yoshida G; Oe S; Banno T; Arima H; Akeda K; Kawamoto E; Imai H; Sakakibara T; Sudo A; Ito Y; Kikuchi T; Osaki S; Tanaka N; Nakanishi K; Kamei N; Kotaka S; Baba H; Okudaira T; Konishi H; Yamaguchi T; Ito K; Katayama Y; Matsumoto T; Matsumoto T; Idota M; Kanno H; Aizawa T; Hashimoto K; Eto T; Sugaya T; Matsuda M; Fushimi K; Nozawa S; Iwai C; Taguchi T; Kanchiku T; Suzuki H; Nishida N; Funaba M; Yamazaki M
BMJ Open; 2018 May; 8(5):e019083. PubMed ID: 29730616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
